2:47 AM
 | 
Nov 13, 2017
 |  BC Extra  |  Company News

Zymeworks, J&J in bispecific antibodies deal

Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) worldwide rights to develop and commercialize up to six bispecific antibodies against Janssen's targets using Zymeworks’ antibody platforms. Janssen will gain...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >